pixlbio

Startup

pixlbio: iPSC-Powered Phenomics

pixlbio is the result of a strategic merger between DefiniGEN Limited (UK) and Phenaros Pharmaceuticals (Sweden), bringing together iPSC expertise and AI-driven phenomics to support pre-clinical drug discovery.

Our Technology Platform: We provide drug screening including MoA studies and toxicity testing, as well as disease modeling using iPSCs enhanced by phenomics technology. Our automated pipeline captures over 1.4M images and profiles 300M+ cells, mapping 3.6 billion morphological features to biological insights with precision and scale - in a week.

Core Offerings:

• iPSC-Derived Models: High-purity hepatocytes, stellates and intestinal organoids, and validated disease models for MASH/MASLD, A1ATD, and Wilson's disease
• Phenomics Platform: AI-powered analysis revealing disease mechanisms, drug responses, and cellular states
• Custom Automation: Proprietary robotics and microscopy systems delivering scalable, high-fidelity results
• SaaS Solutions: Direct access to predictive models and phenomics data

We serve pharmaceutical and biotech companies, as well as research institutions across the globe. Our clients include 11 of the 20 largest global pharma companies.

Company profile:

• ISO 9001:2015 certified operations
• Proprietary pixDiff iPSC-differentation platform for enhanced cell functionality
• Integration of wet-lab robotics, machine learning, and automation
• Track record with commercial success and global pharma partnerships

pixlbio aims to expand beyond liver models into cardiac and renal systems over the upcoming months, and is working to advance predictive, scalable drug discovery platforms.
Reach out to us to arrange a meeting!

website